v3.26.3
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2026
SEGMENT INFORMATION  
SEGMENT INFORMATION

NOTE 16 – SEGMENT INFORMATION

 

The Company determines its reportable segments based on its internal organization structure and internal management reporting used to assess and allocate resources. This information is regularly reviewed by the Company’s Chief Executive Officer who is identified as the Chief Operating Decision Maker (“CODM”). The Company consists of three operating units, BioNexus Gene Lab Corp., MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. which are determined as three reportable segments, as described below. These reportable segments offer different products and services, and are managed separately because they require different technology and marketing strategies. The following describes the operations in each of the Company’s reportable segments:

 

·

Trading of industrial chemicals

-

Includes trading of industrial chemicals

·

Provision for genomic screening services

-

includes in commercializing proprietary blood-based diagnostic test for early disease detection

·

Investment holding

-

Investment holding

 

The CODM evaluates the performance of each reportable segment based on operating income and key segment-specific metrics. There are no inter-segment revenue transactions between reportable segments. Except for investment holding activities and the revenue to the overseas customers as disclosed in Note 12, the Company’s revenue and principal operations are substantially confined within Malaysia.

 

The CODM evaluates segment performance primarily on operating income and reviews the following expense categories by segment: cost of revenue, selling and distribution, and administrative expenses. A reconciliation of total reportable segment amounts to the Company’s consolidated amounts is provided below, with corporate and unallocated items presented as reconciling adjustments.

 

Pursuant to ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, the financial information concerning the Company’s reportable segments is shown as below:

Nine-month periods:

 

By Business Unit

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

Nine-month periods ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$1,961

 

 

$144,954

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(1,250)

 

 

(128,985)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

711

 

 

 

15,969

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

38,273

 

 

 

16,630

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

8,227

 

 

 

1,790

 

 

 

48

 

 

 

10,065

 

Others

 

 

-

 

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

46,500

 

 

 

41,199

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(98,154)

 

 

(2,790)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(180,877)

 

 

(162,031)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

-

 

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(320,767)

 

 

(241,635)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(273,556)

 

 

(184,467)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

-

 

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(273,556)

 

 

(186,041)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(273,556)

 

$(186,041)

 

$(1,424,809)

 

$(1,884,406)

 

 

Provision for

 

 

 

 

 

 

 

 

 

 

 

 

genomic

 

 

Trading of

 

 

 

 

 

 

 

 

 

screening

 

 

industrial

 

 

Investment

 

 

 

 

 

 

services

 

 

chemicals

 

 

holding

 

 

Total

 

 

 

Nine months period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$11,302

 

 

$6,929,849

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(4,995)

 

 

(5,846,956)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

6,307

 

 

 

1,082,893

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

-

 

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

63,646

 

 

 

10,468

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

-

 

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

-

 

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

10,919

 

 

 

136,312

 

 

 

-

 

 

 

147,231

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OTHER INCOME

 

 

74,565

 

 

 

239,164

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(86,275)

 

 

(1,577,214)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(270,725)

 

 

(492,464)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

-

 

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

-

 

 

 

(121,030)

 

 

-

 

 

 

(121,030)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL OPERATING EXPENSES

 

 

(396,572)

 

 

(2,310,207)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(315,700)

 

 

(988,150)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(32)

 

 

(6,266)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(315,732)

 

 

(994,416)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(315,732)

 

$(994,416)

 

$(638,342)

 

$(1,948,490)

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$146,915

 

 

$-

 

 

$146,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(130,235)

 

 

-

 

 

 

(130,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

16,680

 

 

 

-

 

 

 

16,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

54,903

 

 

 

-

 

 

 

54,903

 

Gain from foreign exchange

 

 

10,017

 

 

 

48

 

 

 

10,065

 

Others

 

 

22,779

 

 

 

-

 

 

 

22,779

 

TOTAL OTHER INCOME

 

 

87,699

 

 

 

48

 

 

 

87,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(100,944)

 

 

(22,818)

 

 

(123,762)

Research and development

 

 

(41,736)

 

 

-

 

 

 

(41,736)

General and administrative

 

 

(342,908)

 

 

(600,034)

 

 

(942,942)

Provision for credit losses, net

 

 

(76,814)

 

 

-

 

 

 

(76,814)

Share-based compensation

 

 

-

 

 

 

(799,998)

 

 

(799,998)

TOTAL OPERATING EXPENSES

 

 

(562,402)

 

 

(1,422,850)

 

 

(1,985,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(458,023)

 

 

(1,422,802)

 

 

(1,880,825)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,574)

 

 

(2,007)

 

 

(3,581)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(459,597)

 

 

(1,424,809)

 

 

(1,884,406)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(459,597)

 

$(1,424,809)

 

$(1,884,406)

 

 

By Country

 

Malaysia

 

 

United States

 

 

Total

 

 

 

Nine-month period ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$6,941,151

 

 

$-

 

 

$6,941,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(5,851,951)

 

 

-

 

 

 

(5,851,951)

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

1,089,200

 

 

 

-

 

 

 

1,089,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

 

 

 

 

 

 

 

 

 

 

Dividend income

 

 

21,752

 

 

 

-

 

 

 

21,752

 

Interest income

 

 

74,114

 

 

 

-

 

 

 

74,114

 

Fair value gain on investments in equity securities

 

 

28,256

 

 

 

-

 

 

 

28,256

 

Gain on disposal of investments in equity securities

 

 

42,376

 

 

 

-

 

 

 

42,376

 

Others

 

 

147,231

 

 

 

 

 

 

 147,231

 

TOTAL OTHER INCOME

 

 

313,729

 

 

 

-

 

 

 

313,729

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(1,663,489)

 

 

(37,202)

 

 

(1,700,691)

Research and development

 

 

(39,572)

 

 

-

 

 

 

(39,572)

General and administrative

 

 

(763,189)

 

 

(600,888)

 

 

(1,364,077)

Fair value loss on investments in equity securities

 

 

(119,499)

 

 

-

 

 

 

(119,499)

Provision for credit losses, net

 

 

(121,030)

 

 

-

 

 

 

(121,030)

TOTAL OPERATING EXPENSES

 

 

(2,706,779)

 

 

(638,090)

 

 

(3,344,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,303,850)

 

 

(638,090)

 

 

(1,941,940)

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(6,298)

 

 

(252)

 

 

(6,550)

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS BEFORE TAX

 

 

(1,310,148)

 

 

(638,342)

 

 

(1,948,490)

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

 

$(1,310,148)

 

$(638,342)

 

$(1,948,490)

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$1,643,808

 

 

$4,250,922

 

 

$2,865,971

 

 

$8,760,701

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

163

 

 

 

78,323

 

 

 

-

 

 

 

78,486

 

 

 

 

 

Provision for genomic screening services

 

 

Trading of industrial chemicals

 

 

Investment holding

 

 

Total

 

 

 

As of December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

 

$2,281,947

 

 

$4,577,690

 

 

$2,393,147

 

 

$9,252,784

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Included in the measure of segment assets are:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Addition to non-current assets other than financial instruments and deferred tax assets

 

 

1,382

 

 

 

35,589

 

 

 

-

 

 

 

36,971

 

 

The Company had no inter-segment sales for the periods presented.